Sulfated modification of hyaluronan tetrasaccharide enhances its antitumor activity on human lung adenocarcinoma A549 cells in vitro and in vivo

Protein glycosylation in lung cancer from a mass spectrometry perspective

Lung cancer is a severe disease for which better diagnostic and therapeutic approaches are urgently needed. Increasing evidence implies that aberrant protein glycosylation plays a crucial role in the pathogenesis and progression of lung cancer. Differences in glycosylation patterns have been previously observed between healthy and cancerous samples as well as between different lung cancer subtypes, which suggests untapped diagnostic potential. In addition, understanding the changes mediated by glycosylation may shed light on possible novel therapeutic targets and personalized treatment strategies for lung cancer patients. Mass spectrometry based glycomics and glycoproteomics have emerged as powerful tools for in-depth characterization of changes in protein glycosylation, providing valuable insights into the molecular basis of lung cancer. This paper reviews the literature on the analysis of protein glycosylation in lung cancer using mass spectrometry, which is dominated by manuscripts published over the past 5 years. Studies analyzing N-glycosylation, O-glycosylation, and glycosaminoglycan patterns in tissue, serum, plasma, and rare biological samples of lung cancer patients are highlighted. The current knowledge on the potential utility of glycan and glycoprotein biomarkers is also discussed.

Sulfation on polysaccharides from Zizania latifolia extracted using ultrasound: Characterization, antioxidant and anti-non-small cell lung cancer activities

Zizania latifolia is a highly nutritious vegetable being praised as "Ginseng in Water". Polysaccharides are the main bioactive ingredients in Z. latifolia, but there have been no reports on the yield- and activity-guided ultrasonic-assisted extraction (UAE), sulfation and anti-non-small cell lung cancer (NSCLC) activity. In this study, Z. latifolia polysaccharides (ZLP) were extracted using UAE under an optimized power, followed by sulfation to give three derivatives (SZLP-1 ∼ 3). After characterization, the antioxidant and anti-NSCLC activities were evaluated. The optimal ultrasonic power for ZLP extraction was screened out to be 300 W, under which the yield was 16.9 ± 2.10 %, and the scavenging rate against 2, 2-diphenyl-1-picrylhydrazyl (DPPH) radical was 63.3 ± 5.71 %, significantly higher than those of other powers and hot-water extraction. A series of characterizations fully confirmed the sulfated modification of ZLP. Sulfation improved the antioxidation of ZLP and was positively proportional to the degree of substitution (DS), of which SZLP-2 with a DS of 15.1 ± 2.50 elicited strong hydroxyl and DPPH radicals-scavenging capacities. Meanwhile, SZLP-2 also exerted promising anti-NSCLC potency via inhibiting A549 cell proliferation, with a median inhibition concentration (IC50) of 0.57 ± 0.01 mg/mL at 72 h, markedly smaller than that of unmodified ZLP (0.78 ± 0.04 mg/mL). In summary, the yield- and activity-guided UAE led to the ZLP with high yield and strong antioxidation. Further sulfation enhanced the bioactivities and produced the promising SZLP-2, which showed great potential in the development of novel antioxidant and anti-NSCLC drug.

N-Acetylglucosamine mitigates lung injury and pulmonary fibrosis induced by bleomycin

Lung injury and pulmonary fibrosis contribute to morbidity and mortality, and, in particular, are characterized as leading cause on confirmed COVID-19 death. To date, efficient therapeutic approach for such lung diseases is lacking. N-Acetylglucosamine (NAG), an acetylated derivative of glucosamine, has been proposed as a potential protector of lung function in several types of lung diseases. The mechanism by which NAG protects against lung injury, however, remains unclear. Here, we show that NAG treatment improves pulmonary function in bleomycin (BLM)-induced lung injury model measured by flexiVent system. At early phase of lung injury, NAG treatment results in silenced immune response by targeting ARG1+ macrophages activation, and, consequently, blocks KRT8+ transitional stem cell in the alveolar region to stimulate PDGF Rβ+ fibroblasts hyperproliferation, thereby attenuating the pulmonary fibrosis. This combinational depression of immune response and extracellular matrix deposition within the lung mitigates lung injury and pulmonary fibrosis induced by BLM. Our findings provide novel insight into the protective role of NAG in lung injury.